Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481455 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
A Phase 2 study of Recurrent Glioblastoma Multiforme, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00481455: Completed Phase 2 study of Recurrent Glioblastoma Multiforme, sponsored by CASI pharmaceuticals.
NCT00481455 is a Phase 2 study of Recurrent Glioblastoma Multiforme that has completed, run by CASI pharmaceuticals. The registered enrollment target is 15 participants, below the 101-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481455, a Phase 2 study of Recurrent Glioblastoma Multiforme, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Panzem NCD
Study Locations (1)
North Carolina
- The Brain Tumor Center, Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00481455 record still lists
NCT00481455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 101-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT00481455 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00481455 about?
NCT00481455 is a clinical study titled "Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)". The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
What is the current status of trial NCT00481455?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-04. Estimated completion is 2008-10.
What conditions does trial NCT00481455 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme.
What interventions are being tested in trial NCT00481455?
The interventions under investigation include: Temozolomide (DRUG), Panzem NCD (DRUG).
Who is sponsoring clinical trial NCT00481455?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00481455 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
COMPLETED · Phase 2
-
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
RECRUITING · Phase 1
-
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
COMPLETED · Phase 1
-
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 3
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia